Search

Your search keyword '"Van Den Berg, Leonard"' showing total 3,236 results

Search Constraints

Start Over You searched for: Author "Van Den Berg, Leonard" Remove constraint Author: "Van Den Berg, Leonard"
3,236 results on '"Van Den Berg, Leonard"'

Search Results

1. Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids

3. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

4. Author Correction: The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

6. Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1

7. Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data

8. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study

9. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

12. Comprehensive evaluation of smoking exposures and their interactions on DNA methylation

15. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial

18. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors

19. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.

20. The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases

22. Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosis

25. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

26. 10Kin1day: A Bottom-Up Neuroimaging Initiative

28. Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3′UTR protect against ALS

29. Genetic variants associated with longitudinal changes in brain structure across the lifespan

30. REVEALS—a longitudinal cohort study of multifaceted respiratory assessment in ALS.

31. Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility

32. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis

33. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

34. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial

36. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

37. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

40. DNA Methylation Analysis Identifies Loci for Blood Pressure Regulation

41. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.

43. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

44. Assessment of risk of ALS conferred by the GGGGCC hexanucleotide repeat expansion in C9orf72 among first-degree relatives of patients with ALS carrying the repeat expansion

45. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

46. A comparison between bioelectrical impedance analysis and air-displacement plethysmography in assessing fat-free mass in patients with motor neurone diseases: a cross-sectional study

47. Correction to: The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration (Nature Communications, (2022), 13, 1, (6901), 10.1038/s41467-022-34620-y)

48. Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis

Catalog

Books, media, physical & digital resources